This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: University of Alberta. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Gavin Oudit: Innovator in Cardiovascular Treatments
Introduction
Gavin Oudit is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of cardiovascular medicine through his innovative research and patented inventions. With a total of 2 patents, Oudit's work focuses on the development of modified apelin polypeptides.
Latest Patents
Oudit's latest patents include groundbreaking work on apelin peptides and their uses. The disclosures relate to modified apelin polypeptides that exhibit increased stability against kallikrein, NEP, and ACE2 degradation. These modified peptides also demonstrate enhanced potency compared to the native apelin-13 and apelin-17 polypeptides. Furthermore, the embodiments of these patents disclose methods for utilizing these polypeptides in the treatment of cardiovascular disorders.
Career Highlights
Throughout his career, Gavin Oudit has been associated with prestigious institutions such as the University of Alberta and The Governors of the University of Alberta Tec Edmonton. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Oudit has collaborated with esteemed colleagues, including John C. Vederas and Shaun McKinnie. These partnerships have further enriched his research and innovation efforts.
Conclusion
Gavin Oudit's contributions to the field of cardiovascular treatments through his patented inventions highlight his role as a leading innovator. His work on apelin peptides represents a significant advancement in medical science, showcasing the potential for improved therapies in cardiovascular health.